175
Views
19
CrossRef citations to date
0
Altmetric
Miscellaneous

Syndecan‐1 expression is upregulated in degenerating articular cartilage in a transgenic mouse model for osteoarthritis

, , , &
Pages 469-474 | Received 07 Jan 2005, Accepted 31 Jul 2005, Published online: 12 Jul 2009
 

Abstract

Objective: Mice heterozygous for the Del1 transgene locus with a short deletion mutation in the type II collagen gene develop early‐onset degenerative changes in the knee joints that progress to end‐stage osteoarthritis by the age of 12–15 months. This study focuses on the expression and distribution of syndecan‐1, a cell‐surface heparan sulfate proteoglycan, during the development of osteoarthritic cartilage degeneration, to better understand its role in this disease.

Methods: Northern analyses of total RNA extracted from knee joints of transgenic Del1 mice and their nontransgenic controls were used to monitor changes in syndecan‐1 mRNA levels during development, growth, ageing, and cartilage degeneration. Immunohistochemistry was used to study the distribution of syndecan‐1 in the knee joints at different stages of cartilage degeneration.

Results: Syndecan‐1 mRNA was present in knee joints throughout life, with the highest mRNA levels in ageing knee joints. In Del1 mice, a transient upregulation of syndecan‐1 mRNA synthesis was observed at the age of 6 months coinciding with early stages of cartilage degeneration and a period of attempted repair. Immunostaining for syndecan‐1 was most intense in chondrocytes of superficial and intermediate zones of articular cartilage adjacent to defect areas. Chondrocyte clusters also stained strongly for syndecan‐1.

Conclusion: The present temporospatial expression data on upregulation of syndecan‐1 in articular cartilage during early stages of cartilage degeneration suggest that this molecule is involved in the attempted repair of cartilage fibrillations. Combined with the known role of syndecan‐1 during skeletal development and wound healing, this interesting finding warrants further validation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.